Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$23.45 -2.5%	$21.28	$16.50 ▼ $26.50	$2.04B	N/A	66,918 shs	2,378 shs
AKBA Akebia Therapeutics	$2.53 +1.8%	$2.09	$0.80 ▼ $2.90	$661.01M	0.88	2.83 million shs	976,025 shs
IRON Disc Medicine	$45.59 -1.7%	$46.54	$30.65 ▼ $68.73	$1.58B	0.77	349,043 shs	34,260 shs
TVTX Travere Therapeutics	$20.80 -0.7%	$18.15	$6.01 ▼ $25.29	$1.85B	0.88	1.53 million shs	153,192 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-0.66%	-6.31%	+28.56%	+34.68%	+2,403,999,900.00%
AKBA Akebia Therapeutics	+2.06%	+6.90%	+50.30%	+17.54%	+92.25%
IRON Disc Medicine	-0.56%	+8.52%	+19.67%	-13.59%	+49.47%
TVTX Travere Therapeutics	-2.79%	+4.96%	+44.41%	-9.74%	+230.28%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	4.1487 of 5 stars	4.6	2.0	0.0	4.0	2.1	0.0	0.6
IRON Disc Medicine	2.8929 of 5 stars	4.5	1.0	0.0	0.0	3.0	2.5	0.0
TVTX Travere Therapeutics	2.9294 of 5 stars	4.4	2.0	0.0	0.0	2.9	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
AKBA Akebia Therapeutics	3.20	Buy	$6.63	162.38% Upside
IRON Disc Medicine	3.09	Buy	$98.80	116.74% Upside
TVTX Travere Therapeutics	2.87	Moderate Buy	$31.79	52.85% Upside

Current Analyst Ratings Breakdown

Latest AKBA, AAPG, IRON, and TVTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/12/2025	IRON Disc Medicine	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$112.00 ➝ $120.00
5/2/2025	TVTX Travere Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00
5/2/2025	TVTX Travere Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$22.00 ➝ $23.00
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
4/23/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
4/14/2025	TVTX Travere Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$47.00 ➝ $47.00
4/11/2025	TVTX Travere Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
4/10/2025	TVTX Travere Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $47.00
4/4/2025	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.50 ➝ $7.50
4/3/2025	TVTX Travere Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	2.08	N/A	N/A	N/A	∞
AKBA Akebia Therapeutics	$160.18M	4.13	N/A	N/A	($0.16) per share	-15.78
IRON Disc Medicine	N/A	N/A	N/A	N/A	$14.17 per share	N/A
TVTX Travere Therapeutics	$273.53M	6.75	N/A	N/A	$2.67 per share	7.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	-$51.92M	-$0.21	N/A	N/A	N/A	-27.07%	N/A	-20.57%	N/A
IRON Disc Medicine	-$76.43M	-$3.92	N/A	N/A	N/A	N/A	-25.24%	-23.96%	N/A
TVTX Travere Therapeutics	-$111.40M	-$2.81	N/A	N/A	N/A	-137.90%	-1,636.87%	-55.95%	N/A

Latest AKBA, AAPG, IRON, and TVTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
5/7/2025	Q1 2025	IRON Disc Medicine	-$0.99	-$1.02	-$0.03	-$1.02	N/A	N/A
5/1/2025	Q1 2025	TVTX Travere Therapeutics	-$0.55	-$0.47	+$0.08	-$0.47	$77.44 million	$81.73 million
3/13/2025	Q4 2024	AKBA Akebia Therapeutics	-$0.05	-$0.10	-$0.05	-$0.10	$37.36 million	$46.50 million
2/27/2025	Q4 2024	IRON Disc Medicine	-$1.06	-$0.98	+$0.08	-$0.98	N/A	N/A
2/20/2025	Q4 2024	TVTX Travere Therapeutics	-$0.58	-$0.73	-$0.15	-$0.73	$72.38 million	$74.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
IRON Disc Medicine	N/A	N/A	N/A	N/A	N/A
TVTX Travere Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	1.52	1.21
IRON Disc Medicine	N/A	19.36	19.36
TVTX Travere Therapeutics	24.96	1.71	1.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
AKBA Akebia Therapeutics	33.92%
IRON Disc Medicine	83.70%
TVTX Travere Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
AKBA Akebia Therapeutics	4.10%
IRON Disc Medicine	4.24%
TVTX Travere Therapeutics	4.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.07 million	N/A	N/A
AKBA Akebia Therapeutics	430	261.79 million	209.24 million	Optionable
IRON Disc Medicine	30	34.57 million	28.50 million	Not Optionable
TVTX Travere Therapeutics	460	88.81 million	75.12 million	Optionable

AKBA, AAPG, IRON, and TVTX Headlines

Recent News About These Companies

Integral Health Asset Management LLC Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 14 at 6:18 AM | marketbeat.com

J. Goldman & Co LP Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 14 at 5:59 AM | marketbeat.com

Jacobs Levy Equity Management Inc. Has $37.88 Million Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 14 at 5:58 AM | marketbeat.com

Schonfeld Strategic Advisors LLC Sells 152,820 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 13 at 3:48 AM | marketbeat.com

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 12 at 5:00 PM | businesswire.com

Brevan Howard Capital Management LP Sells 30,742 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 12 at 4:45 AM | marketbeat.com

1,209,810 Shares in Travere Therapeutics, Inc. (NASDAQ:TVTX) Purchased by BNP Paribas Financial Markets

May 12 at 4:16 AM | marketbeat.com

Driehaus Capital Management LLC Has $38.64 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 11 at 6:39 AM | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Crestline Management LP

May 10, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Stake Boosted by AQR Capital Management LLC

May 10, 2025 | marketbeat.com

Hsbc Holdings PLC Has $487,000 Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 9, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells $37,279.55 in Stock

May 8, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Sells $37,553.20 in Stock

May 8, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) CEO Sells $398,350.20 in Stock

May 8, 2025 | marketbeat.com

Travere Therapeutics to Participate at Upcoming Investor Conferences

May 7, 2025 | businesswire.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 1,771 Shares

May 7, 2025 | insidertrades.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $31.79 Average Price Target from Analysts

May 7, 2025 | americanbankingnews.com

Freestone Grove Partners LP Takes Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

May 6, 2025 | marketbeat.com

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of "Moderate Buy" from Analysts

May 6, 2025 | marketbeat.com

Travere Therapeutics (NASDAQ:TVTX) Posts Earnings Results, Beats Expectations By $0.08 EPS

May 5, 2025 | marketbeat.com

Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report

May 4, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
By Jeffrey Neal Johnson | April 25, 2025
View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
By Chris Markoch | April 16, 2025
View Gold Rally Continues: These 3 Mining Stocks Are Likely to Benefit
CrowdStrike Stock Is a Buy as Cyberthreat Environment Expands
By Chris Markoch | April 15, 2025
View CrowdStrike Stock Is a Buy as Cyberthreat Environment Expands
Medtronic: A Dividend Aristocrat With Stability and Innovation
By Jeffrey Neal Johnson | April 22, 2025
View Medtronic: A Dividend Aristocrat With Stability and Innovation

AKBA, AAPG, IRON, and TVTX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$23.45 -0.59 (-2.45%)

As of 10:19 AM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Akebia Therapeutics NASDAQ:AKBA

$2.52 +0.05 (+1.81%)

As of 11:16 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Disc Medicine NASDAQ:IRON

$45.58 -0.77 (-1.65%)

As of 11:15 AM Eastern

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Travere Therapeutics NASDAQ:TVTX

$20.80 -0.14 (-0.69%)

As of 11:16 AM Eastern

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time